TACROLIMUS

Generic: TACROLIMUS

E. Fougera & Co. a division of Fougera PharmaceuticalsManufacturer
TOPICALRoute
TACROLIMUSActive Substance
2014-09-09Original Approval

TACROLIMUS is FDA application ANDA200744, sponsored by FOUGERA PHARMS INC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class III2020-03-23
Tacrolimus Capsules, USP 5mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-2047

Presence of foreign tablet/capsule - Potential presence of commingled one Tacrolimus 1 mg capsule in

Class II2023-02-08
Tacrolimus Capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Mfd. by Dr. Reddy's Laboratories Limited, Bachupally - 500

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle

Class III2020-12-22
NDC 64380-721-06 TACROLIMUS CAPSULES, USP 1mg 100 Capsules Rx Only Manufactured by: Strides Pharma Science Ltd. Bengalur

Failed Moisture Limits

Class II2012-06-29
Mylan, Tacrolimus Capsules 0.5 mg, 100 count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 NDC 0378-

Failed USP Content Uniformity Requirements: OOS result reported on retained samples.

Class III2022-07-11
Tacrolimus Ointment, 0.1%, For Dermatological Use Only, Not for Ophthalmic Use, Rx Only, a) 30 g tube, NDC 68462-534-35,

Defective Container: Tube split from side seam

Class II2023-12-15
Tacrolimus Capsules, USP 1mg, 100-Count Bottles, Rx Only, Manufactured by: Dr. Reddy's Laboratories Limited, Bachupally,

Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrol

Class II2013-10-22
Tacrolimus Capsules, USP, 0.5 mg, 100 capsules/bottle, Rx only, Manufactured in India by Sandoz Private ltd. for Sandoz

Cross Contamination with Other Products: findings of carryover of trace amounts of a previously manu

Top Reported Reactions

1
OFF LABEL USE
13,183 reports
2
DRUG INEFFECTIVE
9,050 reports
3
PRODUCT USE IN UNAPPROVED INDICATION
6,162 reports
4
DRUG INTERACTION
5,626 reports
5
ACUTE KIDNEY INJURY
5,528 reports
6
DIARRHOEA
4,584 reports
7
TRANSPLANT REJECTION
4,146 reports
8
CYTOMEGALOVIRUS INFECTION
4,080 reports
9
PYREXIA
3,872 reports
10
COVID-19
3,755 reports